Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation

Poisson, M; Pouillart, P; Bataini, J. P.; Mashaly, R; Pertuiset, B; Metzger, J

doi:10.1007/bf01401791

Cited by 19 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical data on glioma therapy have been contradictory (35,41,44,45). Our own in vitro results are also somewhat disappointing: 5/12 tumors tested did not show any doses-response relation (in one of these constant "tumor proliferation enhancement was observed), the remaining seven tumors showed some response, more pronounced in RNA-synthesis -all results being at best moderate.…”

Section: Discussionmentioning

confidence: 99%

Chemosensitivity of malignant human brain tumors

Bogdahn

1983

J Neuro-Oncol

View full text Add to dashboard Cite

Tumor cell proliferation and morphological changes in tumor cells under the influence of different cytostatic agents were measured in an in vitro assay to determine chemosensitivity of human malignant brain tumors. Aliquots of 2 to 5 x 10(4) cells of a tumor cell suspension (prepared from biopsy specimen by mechanical and enzymatic disintegration) were incubated for 72 hr in the presence of different cytostatic agents. After another nine days of incubation in fresh medium, cell proliferation was calculated by incorporation of 14C-leucine and 3H-uridine and measurement in a liquid scintillation counter. Morphological changes in tumor cells were evaluated in Labtek tissue culture slides cultured under identical conditions. All drugs were tested in pharmacologically achievable concentrations. In vitro BCNU-sensitivity of 7/17 patients correlated with a postoperative recurrence free interval of 15.1 months, in vitro BCNU-resistance of 10/17 patients correlated with a postoperative recurrence free interval of 6.38 months (p less than 0.001). Tumors of lower grades of malignancy (astrocytoma III, malignant ependymoma, medulloblastoma) in our series have a statistically significant higher median BCNU-sensitivity (63.5%, p less than 0.05) and are sensitive to more drugs (3.6 drugs, median out of six selected drugs, p less than 0.01) than tumors of higher grades of malignancy (astrocytoma IV, glioblastoma multiforme; 29.54% BCNU-sensitivity, 1.4 effective drugs). In our series differences of BCNU-tumor sensitivity and number of effective drugs were not statistically significant if related to age and sex of tumor bearing patients. We think this assay provides the opportunity to test a large number of drugs in a very short period of time. Results may indicate alternative drug regimen for those patients resistant to conventional chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemosensitivity of malignant human brain tumors

Bogdahn

1983

J Neuro-Oncol

View full text Add to dashboard Cite

show abstract

“…An increased neurotoxicity with the combined treatment has never been formally proved, but some observations suggest that the neurotoxic risk of combined treatment may be higher than treatment with radiotherapy alone [57,76].…”

Section: Nitrosoureasmentioning

confidence: 99%

Neurological complications of radiotherapy and chemotherapy

Keime-Guibert

Napolitano

Delattre

1998

Journal of Neurology

228

130

View full text Add to dashboard Cite

Neurological complications of radiotherapy and chemotherapy can affect the central or peripheral nervous system. Most are dose-dependent and constitute a limiting factor in the administration of treatments. Radiation-induced neurological complications are classified as acute, early-delayed or delayed. The most important are radionecrosis and cognitive dysfunction/leukoencephalopathy. Neurotoxicity of chemotherapy is frequent and depends upon dose, type of drugs (especially cisplatin and methotrexate) and their combination with radiotherapy.

show abstract

“…2 at the time of their death none showed any neurologic symptoms. The autopsy of the first one showed no recurrence of the tumor.…”

Section: Discussionmentioning

confidence: 93%

Two cases of acute leukemia following treatment of malignant glioma

Genot

Krulik

Poisson

et al. 1983

Cancer

Self Cite

View full text Add to dashboard Cite

Two female patients, 42 and 30 years old, respectively, died of acute nonlymphocytic leukemia 43 and 38 months, respectively, after a subsequent treatment: chemotherapy for one and irradiation and chemotherapy for the other, following excision of a malignant glioma. At the time of death, both seemed to be in complete remission of their brain tumor. Both had been treated with procarbazine and nitrosoureas. The latter were responsible for severe myelosuppressive episodes and seem to have played an essential role in the induction of the leukemia. In one case, a myelodysplasia was observed before the onset of the AL and the diagnosis of refractory anemia with excess of blasts seemed warranted. Secondary acute leukemias are rare in the evolution of malignant gliomas and the usefulness of subsequent radiochemotherapy cannot be questioned at the present time. The risks involved in this therapy are minor when compared to the short‐term fatal prognosis of this type of tumor. Cancer 52:222‐226, 1983.

show abstract

Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation

Cited by 19 publications

References 18 publications

Chemosensitivity of malignant human brain tumors

Chemosensitivity of malignant human brain tumors

Neurological complications of radiotherapy and chemotherapy

Two cases of acute leukemia following treatment of malignant glioma

Contact Info

Product

Resources

About